MARKET NEWS AND UPDATES.
Get notified for Latest News and Market Alerts.
Get notified for Latest News and Market Alerts.
×
CMP as on 01-Jul-22 16:00
₹ 4,385.90Open
₹ 4,385.00Turnover (lac)
₹ 13,368Prev. Close
₹ 4,393.80Day's Vol (shares)
₹ 3,04,799CMP as on01-Jul-22 16:01
₹ 4,384.35Open
₹ 4,370.05Turnover (lac)
₹ 332Prev. Close
₹ 4,399.90Day's Vol (shares)
₹ 7,577CMP as on 01-Jul-22 0:00
₹ 4,358.00Open
₹ 4,245.00Open Interest(Contracts)
₹ 17,66,125VWAP
₹ 4,316.57Day's Vol (shares)
₹ 4,87,625On June 28, 2022 the U.S. Court dismissed all claims and counterclaims pending in the case with prejudice.
Dr Reddys Laboratories files Annual Report with SEC
Nifty Financial Services dipped nearly 1%, while Bank Nifty also followed with more than 0.6% downside.
The acquisition will complement Dr. Reddy's U.S. institutional business with limited competition injectable products.
Dr Reddys settles litigation related to its generic buprenorphine and naloxone sublingual film
Dr Reddys settles litigation related to its generic buprenorphine and naloxone sublingual film
According to LIC, the ownership climbed by 2.002% from 3.644% to 5.646% from September 3, 2021 to June 15, 2022, at an average cost of
Dr. Reddy's stock rises, and investors welcome the FDA's approval of cancer medication in the United States.
Dr. Reddys Sorafenib Tablets, USP, are available in 200 mg tablets in bottle count sizes of 120.
Dr. Reddys launches Sorafenib Tablets in US market
Per Order for ETF & Mutual Funds Brokerage
Per Order for Delivery, Intraday, F&O, Currency & Commodity
